Welcome to Medilinks

Medilinks Inc is a facilitator of specialized Genomic and Genetic testing’s which help and guide
Physicians during patients treatment. Medilinks Inc founded in 2007.

Oncotype IQ

Our portfolio of tests and services is aimed at delivering genomic intelligence that optimizes treatment decisions and outcomes throughout the cancer patient journey.

Over One Million Patients Tested

In collaboration with physicians around the world, we have delivered more than 1 million Oncotype DX tests to cancer patients worldwide since we made our first test available to patients in 2004.

After TAILORx, updated guidelines and HTA body recommendations clearly position
Oncotype DX Breast Recurrence Score® test as the “preferred” assay

New

NCCN®a

Only assay recognized by NCCN Guidelines to predict adjuvant chemotherapy benefit and the only assay classified as the “preferred” multigene test in node-negative patients with HR-positive, HER2-negative breast cancer1

New

IQWiG

With the results of TAILORx, only Oncotype DX® has sufficient evidence to guide adjuvant chemotherapy decisions in patients with early-stage, node-negative, invasive
breast cancer2

New

NICEa

Only test considered to predict chemotherapy benefit, therefore providing a cost-effective option in patients with early-stage, node-negative and micrometastatic
breast cancer3

St Gallenb,c

The multi-gene assay endorsed by most
panelists for guiding treatment decisions on adjuvant chemotherapy both in node-negative and in node-positive early breast cancer4

ASCO®a,c

May be used to guide decisions on adjuvant systemic chemotherapy in node-negative patients with ER-positive, HER2-negative breast cancer5

ESMO®a,c

May be used to gain additional prognostic and/or predictive information to
complement pathology assessment and to predict the benefit of adjuvant chemotherapy6

“Oncotype DX assay, only test with evidence for additional benefit in guiding treatment
in early HR+, HER2-, N0 breast cancer”, IQWIG Press Release, Sept. 20182
The Oncotype DX test helps identify patients who will benefit from adjuvant chemotherapy, or not
3 pieces of information provided by the test
What is the
Recurrence Score result
of your patient?
What is the distant
recurrence risk at 9 years
of your patient?a
What absolute
chemotherapy benefit
can we expect for your
patient?a

We constantly strive to anticipate the aspiration
of our consumer and respond creatively With branded products

OUR TEAM

This is our dedicated team who work day-in and day-out together to bring
our clients the most amazing projects for a digitally connected world.

The people who have trusted us so far

CONTACT US

Medilinks Inc is a facilitator of specialized Genomic and Genetic testing’s which help and guide Physicians during patients treatment.

803, Naman Midtown, 8th Floor, B – wing, Senapati Bapat Marg, Prabhadevi, Mumbai – 400013.

Fill out this field
Fill out this field
Fill out this field
Menu